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Background: This Phase III, randomized, double-blind, placebo-controlled study investigated the efﬁcacy
and tolerability of ﬂexibly-dosed cariprazine in patients with acute manic or mixed episodes associated
with bipolar I disorder.
Methods: Patients were randomized to 3 weeks of double-blind treatment with cariprazine 3–12 mg/day
(n¼158) or placebo (n¼154). The primary efﬁcacy parameter was change from baseline to Week 3 in
Young Mania Rating Scale (YMRS) total score. The secondary efﬁcacy parameter was change from
baseline to Week 3 in Clinical Global Impressions-Severity (CGI-S) score.
Results: Mean change from baseline to Week 3 in YMRS total score was signiﬁcantly greater for patients
receiving cariprazine 3–12 mg/day versus placebo (P¼0.0004). Signiﬁcant differences between groups in
YMRS total score mean change were observed by Day 4 (ﬁrst postbaseline assessment) and maintained
throughout double-blind treatment (all assessments, Po0.01). Cariprazine also demonstrated statisti-
cally signiﬁcant superiority over placebo on YMRS response (Z50% improvement: cariprazine, 58.9%;
placebo, 44.1%; P¼0.0097) and remission (YMRS total scorer12: cariprazine, 51.9%; placebo, 34.9%;
P¼0.0025) and mean change in CGI-S (P¼0.0027) score and Positive and Negative Syndrome Scale
(PANSS) (P¼0.0035) total score. The most common cariprazine-related (Z10% and twice placebo)
treatment emergent adverse events (TEAEs) were akathisia, extrapyramidal disorder, tremor, dyspepsia,
and vomiting. Mean change from baseline in metabolic parameters were generally small and similar
between groups.
Limitations: Lack of active comparator arm; short duration of study.
Conclusion: In this study, cariprazine 3–12 mg/day was effective and generally well tolerated in the
treatment of manic and mixed episodes associated with bipolar I disorder.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Bipolar I disorder is a chronic, disabling, and multidimensional
illness characterized by the occurrence of acute manic or mixed
episodes. Patients experience a highly variable course of illness that
may include a combination of recurrent manic and/or depressive
episodes as well as additional symptoms and comorbidities, such as
psychotic symptoms, cognitive impairment, anxiety disorders, or
substance abuse disorders (Sachs et al., 2011).
Antipsychotics are a ﬁrst-line treatment option for bipolar
mania but the complex pathophysiology of the disease presents
a major clinical challenge since many patients do not achieve full
remission and recovery following treatment (Sachs et al., 2011;
Sachs and Rush, 2003). While all antipsychotics are thought to
confer antimanic efﬁcacy via blockade of dopamine D2 receptors,
pharmacological proﬁles vary between antipsychotics and these
differences may affect efﬁcacy and/or tolerability. For example,
antagonism at the histamine H1 receptor is linked to sedation
(Richelson, 2010) and weight gain (Kroeze et al., 2003; Richelson,
2010). New antipsychotics with unique receptor proﬁles and
mechanisms of action are needed to provide robust efﬁcacy with
early onset of action coupled with good tolerability.
Cariprazine is an orally active and potent dopamine D3 and D2
receptor partial agonist with preferential binding to D3 receptors.
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Cariprazine also shows partial agonist activity at 5-HT1A, antagon-
ism at 5-HT2B, relatively lower afﬁnity for 5-HT2A, 5-HT2C, adre-
nergic α1, and histamine H1 receptors, and negligible afﬁnity for
other receptors (Kiss et al., 2010). Cariprazine is distinct from other
atypical antipsychotics as it shows greater in vitro afﬁnity for the
D3 versus D2 receptor with almost 10-fold higher D3 receptor
selectivity (Kiss et al., 2010). In vivo, cariprazine demonstrates high
and balanced occupancy at both D2 and D3 receptors (Kiss et al.,
2012); evidence suggests that other antipsychotics may not show
signiﬁcant occupancy of the D3 receptor in vivo at clinically
relevant doses (Graff-Guerrero et al., 2009; McCormick et al.,
2010; Mizrahi et al., 2011).
The D3 receptor is thought to play a role in regulating mood
and cognition, and activity at the dopamine D3 receptor may
provide additional beneﬁts in managing the broad symptoms
associated with bipolar disorder (Cho et al., 2010; Gross and
Drescher, 2012; Joyce and Millan, 2005; Laszy et al., 2005; Leggio
et al., 2013). Cariprazine, with potent partial agonist activity at D3,
D2, and 5-HT1A receptors and low or negligible afﬁnity at other
receptors, may confer broad efﬁcacy across mania symptoms with
a favorable tolerability proﬁle in patients with bipolar disorder.
Cariprazine was investigated in 2 previous 3-week, Phase II/III
clinical trials in patients with acute manic or mixed episodes
associated with bipolar I disorder (Calabrese et al., in press;
Durgam et al., 2014). In both studies, cariprazine demonstrated
strong efﬁcacy in improving the symptoms of acute mania and was
generally well tolerated. This Phase III study (NCT01058096) was
designed to further investigate the efﬁcacy, safety, and tolerability
of cariprazine 3–12 mg/day in patients with acute mania asso-
ciated with bipolar I disorder.
2. Methods
This study was conducted at 28 study centers in the United
States (10) and India (18) from February 2010 to July 2011 in
accordance with the Declaration of Helsinki and Good Clinical
Practice guidelines. The study protocol was approved by each site's
institutional review board (United States) or ethics committee
(India) and patients gave informed, written consent.
2.1. Study design
This study was a 3-week, randomized, double-blind, placebo-
controlled, parallel-group, ﬂexible-dose study conducted to eval-
uate the efﬁcacy, safety, and tolerability of cariprazine 3–12 mg/
day in patients with acute manic or mixed episodes associated
with bipolar I disorder. The study comprised 3 phases: a no-drug
washout period of 4–7 days, a 3-week double-blind treatment
phase, and a 2-week safety follow-up period. Eligible patients
were randomized (1:1) to cariprazine or placebo. Patients rando-
mized to cariprazine received a starting dose of 1.5 mg/day (Day 0)
with a dose increase to 3.0 mg/day on Day 1; on Day 2, dosage
could be increased to 6 mg/day for 2 days based on patient
response (investigator judgment) and tolerability. Thereafter, at
assessments corresponding to Days 4, 7, 10, and 14, patients with
o50% improvement in Young Mania Rating Scale (YMRS) total
score (Young et al., 1978) and no signiﬁcant tolerability issues
received further dose increases in 3 mg/day increments to a
maximum of 12 mg/day; no dose increases were permitted after
Day 14. In the event of tolerability concerns, dose decreases in
3 mg/day decrements to a minimum of 3 mg/day were allowed.
Patients were voluntarily hospitalized during the washout
period and for at least 14 days of the 3-week double-blind
treatment phase. Starting on Day 14, patients could be discharged
and treated as outpatients if the following criteria were met:
Clinical Global Impressions-Severity (CGI-S) (Guy, 1976b) score
r3 (mildly ill), no signiﬁcant risk of suicide or violent behavior,
and ready for discharge in the opinion of the Investigator. Follow-
ing double-blind treatment or premature discontinuation, there
was a 2-week safety follow-up period during which patients
received treatment as usual at the discretion of the Investigator.
2.2. Inclusion/exclusion criteria
Men and women (18–65 years of age) with a diagnosis of
bipolar I disorder, manic or mixed type, with or without psychotic
symptoms, based on the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision (DSM-IV-TR)(American
Psychiatric Association, 2000) were eligible for the study; patients
experiencing their ﬁrst manic episode or meeting criteria for rapid
cycling were excluded. Additional criteria for eligibility included
YMRS total score Z20, with a score Z4 on at least 2 of the
following items: irritability, speech, content, and disruptive/
aggressive behavior; a Montgomery-Åsberg Depression Rating
Scale (MADRS) (Montgomery and Åsberg, 1979) total score o18;
and body mass index (BMI) of 18–40 mg/kg. Women of child-
bearing potential could not be pregnant, nursing or have a positive
pregnancy test at screening.
Patients with substance- or medical condition-induced mania,
principal Axis I diagnoses other than bipolar I, or Axis II diagnoses
of sufﬁcient severity to interfere with study participation were
excluded. Additional exclusion criteria included alcohol or sub-
stance abuse/dependence within the prior 3 months, suicide risk,
or signiﬁcant medical conditions that in the judgment of the
investigator could interfere with the study or endanger the
patient’s well-being. Patients who had received electroconvulsive
therapy or a depot neuroleptic within 3 months of screening, been
treated with clozapine within the last 10 years, or received
cariprazine in a previous investigational study were also excluded.
Use of other psychotropic medications was generally prohib-
ited with the exception of zolpidem, zaleplon, chloral hydrate, or
eszopiclone for insomnia; diphenhydramine, benztropine (or
similar anticholinergic), or propranolol for akathisia; or lorazepam
(or diazepam) for control of agitation.
2.3. Assessments
The YMRS and CGI-S scale were administered at all study visits
(screening, baseline/Day 0, Days 4, 7, 10, 14, 21). Other efﬁcacy
assessments included the Clinical Global Impressions-Improve-
ment (CGI-I) (Guy, 1976b) scale (Days 4, 7, 10, 14, 21), MADRS
(screening, baseline/Day 0, Days 7, 14, 21), and Positive and
Negative Syndrome Scale (PANSS) (Kay et al., 1987) (baseline/Day
0, Days 7, 14, 21).
Safety evaluations included the recording of adverse events
(AEs), clinical laboratory tests, 12-lead electrocardiogram (ECG),
weight, vital signs, and the Columbia-Suicide Rating Scale (C-SSRS)
(Posner et al., 2011). Extrapyramidal symptoms (EPS) were
assessed with the Abnormal Involuntary Movement Scale (AIMS)
(Guy, 1976a), Barnes Akathisia Rating Scale (BARS) (Barnes, 1989),
and Simpson-Angus Scale (SAS) (Simpson and Angus, 1970).
2.4. Statistical methods
Safety analyses were performed on the Safety Population (all
randomized patients who received Z1 dose of double-blind
medication). Efﬁcacy analyses were based on the Intent-to-Treat
(ITT) Population (all patients in the Safety Population with Z1
postbaseline YMRS total score assessment).
The primary and secondary efﬁcacy parameters were change
from baseline to Week 3 in YMRS total score and CGI-S score,
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respectively. Primary and secondary analyses were performed
using a mixed-effects model with repeated measures (MMRM)
with treatment group, study center, assessment day, and
treatment-group-by-assessment day interaction as ﬁxed effects
and baseline score and baseline-by-assessment day interaction as
covariates; an unstructured covariance matrix was used to model
the covariance of within-patient scores. Sensitivity analyses were
conducted on the primary efﬁcacy outcome using 2 different
models, a pattern-mixture model (PMM) based on nonfuture-
dependent missing value restrictions (Kenward et al., 2003) and an
analysis of covariance model (ANCOVA) with treatment group and
study center as factors and the baseline YMRS total score as the
covariate; for the ANCOVA model, missing values were imputed
using the last observation carried forward (LOCF) approach.
Cohen's d effect sizes were calculated post hoc for the primary
efﬁcacy parameter for both the MMRM and ANCOVA/LOCF models.
Additional efﬁcacy parameters included change from baseline
to Week 3 in MADRS total score and PANSS total score, CGI-I score
at Week 3 (using baseline CGI-S as a covariate), and YMRS
response (Z50% improvement from baseline) and remission
(score r12) rates at Week 3. Continuous variables were analyzed
using an MMRM model similar to the primary analysis; response
and remission rates were analyzed using a logistic regression
model with baseline YMRS score and treatment group as expla-
natory variables and missing values imputed by LOCF approach.
All statistical tests were 2-sided with a 5% signiﬁcance level; all
conﬁdence intervals (CIs) were 2-sided 95% CIs. The primary and
secondary efﬁcacy parameters were controlled for multiple com-
parisons, with formal hypothesis testing (α¼0.05) on the second-
ary outcome performed only if the primary efﬁcacy parameter was
positive (α¼0.05). Statistical signiﬁcance was deﬁned as P values
o0.05 for all parameters.
Between-group comparisons for demographic and baseline
characteristics were analyzed using a 2-way analysis of variance
(ANOVA) model for continuous variables and Cochran–Mantel–
Haenszel (CMH) (Johnson and May, 1995) test for categorical
variables; differences between treatment groups for discontinua-
tions were carried out using the Fisher exact test (Mehta et al.,
1984). Safety parameters were summarized using descriptive
statistics (eg, frequency distribution, mean, standard deviation).
3. Results
3.1. Patient disposition and demographics
Patient disposition is summarized in Table 1. Completion rates
were similar between treatment groups. Slightly more patients in
the cariprazine group compared with placebo discontinued due to
withdrawal of consent or AEs, although differences were not
signiﬁcant; placebo-treated patients discontinued due to insufﬁ-
cient therapeutic response more frequently than cariprazine-
treated patients (P¼0.052).
Baseline demographic and clinical characteristics were similar
between treatment groups (Table 1). The mean baseline YMRS
total score was approximately 32 in both treatment groups
(Table 2), indicating a moderately to severely ill patient population
(Young et al., 1978). In the cariprazine treatment group, 9%, 22%,
30%, and 39% of patients received a ﬁnal daily dose of 3 mg/day,
6 mg/day, 9 mg/day, or 12 mg/day respectively.
3.2. Efﬁcacy
Cariprazine compared with placebo demonstrated statistically
signiﬁcantly greater reductions in YMRS total score at Week 3
(Fig. 1A, Table 2). Statistically signiﬁcant greater improvement in
YMRS score for cariprazine relative to placebo was observed at the
ﬁrst postbaseline assessment (Day 4) and continued through the
end of the trial. Sensitivity analyses using PMM and ANCOVA/LOCF
approaches supported the primary result. Effect sizes for caripra-
zine versus placebo on change from baseline in YMRS were 0.45
and 0.40 using MMRM and LOCF approaches, respectively.
At Week 3, mean change from baseline in CGI-S score was
signiﬁcantly greater for cariprazine compared with placebo
(Table 2). Signiﬁcant difference between groups was evident as
early as Day 4 and was maintained through the end of double-
blind treatment (Fig. 1B).
CGI-I and PANSS total score changes at Week 3 were signiﬁ-
cantly greater in the cariprazine treatment group relative to
placebo (Table 2). Mean MADRS scores at baseline were low and
mean changes in MADRS scores were small during the study;
between-group differences in MADRS total scores were not statis-
tically signiﬁcant (Table 2). Signiﬁcantly more cariprazine-treated
patients than placebo-treated patients met criteria for response
and remission at Week 3 (Table 2).
3.3. Safety and tolerability
An overall summary of AEs and frequent treatment-emergent AEs
(TEAEs) (Z5% in either treatment group) reported during double-
blind treatment are presented in Table 3. The only TEAEs that led to
the discontinuation of 2 or more patients in either treatment group
were worsening of mania (placebo¼5; cariprazine¼2), akathisia
(placebo¼0; cariprazine¼5), and rash (placebo¼2; cariprazine¼0).
Most TEAEs were mild or moderate in intensity (placebo, 98.9%;
cariprazine, 97.2%). Of patients with SAEs during the double-blind
Table 1
Patient disposition, demographics, and baseline characteristics.
Placebo Cariprazine
3–12 mg/day
Patient dispositiona
Randomized population, n 154 158
Safety population, n 154 158
Intent-to-treat population, n 152 158
Completed study, n (%) 106 (68.8) 108 (68.4)
Reason for premature discontinuation, n (%)
Adverse events 11 (7.1) 15 (9.5)
Insufﬁcient therapeutic response 16 (10.4) 7 (4.4)
Protocol violation 2 (1.3) 1 (0.6)
Withdrawal of consent 17 (11.0) 26 (16.5)
Lost to follow-up 0 1 (0.6)
Other 2 (1.3) 0
Demographics (safety population)
Age, mean (SD), years 36.7 (11.8) 35.8 (11.4)
Men, n (%) 95 (61.7) 105 (66.5)
Race, n (%)
White 33 (21.4) 33 (20.9)
Black 29 (18.8) 33 (20.9)
Asian 88 (57.1) 91 (57.6)
Other 4 (2.6) 1 (0.6)
Weight, mean (SD), kg 71.9 (20.3) 69.6 (20.1)
Body mass index, mean (SD), kg/m2 25.7 (6.0) 25.2 (6.0)
Disorder characteristics (safety population)
Duration of bipolar I disorder, mean (SD), years 10.9 (8.2) 10.0 (9.1)
Age at onset, mean (SD), years 25.8 (10.1) 25.9 (10.4)
Duration of current manic episode, n (%)
r7 days 25 (16.2) 18 (11.4)
47r14 days 67 (43.5) 77 (48.7)
414r21 days 22 (14.3) 18 (11.4)
421 days 40 (26.0) 45 (28.5)
a Good clinical practice violations were identiﬁed at 1 study center (n¼11);
these patients were excluded from all analyses.
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period, all 5 cariprazine patients and 1 of 3 placebo patients
discontinued treatment as a result of the event; worsening of mania
was the only SAE reported in more than 1 patient (placebo¼1;
cariprazine¼2). Use of benzodiazepines as a rescue medication to
control agitation was slightly higher in the placebo group (81%) than
in the cariprazine group (75%).
Mean changes in clinical laboratory parameters and vital signs
are summarized in Table 4. The cariprazine treatment group was
associated with slightly higher mean increases than placebo in
fasting glucose (6.2 versus 1.1 mg/dL); the percentage of patients
that shifted from normal glucose levels (o100 mg/dL) at baseline
to high glucose levels (Z126 mg/dL) at the end of treatment was
3.0% for the cariprazine group compared with 0% for the placebo
group. The incidence of patients with a Z7% increase in body
weight was the same for placebo and cariprazine (both 2%).
Potentially clinically signiﬁcant (PCS) values for supine blood
pressure and pulse rate were infrequent in all treatment groups
(o1%). The incidence of orthostatic hypotension (Z20 mmHg
decrease in systolic blood pressure or Z10 mmHg decrease in
diastolic blood pressure when changing from supine to standing)
was similar for placebo (9%) and cariprazine (10%). Mean changes
in QT interval were small and similar between groups (QTcB:
placebo, þ0.3; cariprazine, þ2.4; QTcF: placebo, 1.2; caripra-
zine, 3.5). No patient had a QTcF interval4500 msec in either
group; 1 patient in the placebo group had a QTcB inter-
val4500 msec. No signiﬁcant cardiac TEAEs (eg, abnormal ECG,
congestive heart failure, ventricular ﬂutter) were reported.
Mean changes in AIMS, BARS, and SAS total scores were slightly
higher in the cariprazine group compared with placebo (Table 4).
A total of 6 (4%) placebo-treated patients and 30 (19%) cariprazine-
treated patients experienced treatment-emergent EPS (parkinson-
ism) (SAS score r3 at baseline and 43 at any postbaseline
assessment) during double-blind treatment; 8 placebo-treated
patients (5%) and 36 cariprazine-treated patients (23%) experi-
enced treatment-emergent akathisia (BARS score r2 at baseline
and 42 at any postbaseline assessment). Use of medication to
control EPS was higher in the cariprazine group (37%) than placebo
(7%). EPS-related TEAEs including akathisia and restlessness were
generally mild or moderate in intensity (cariprazine, 92%;
placebo, 100%).
There were no reports of suicidal behavior or overdoses during
the study. TEAEs of suicidal ideation were reported in 2 cariprazine
and 2 placebo patients. Based on C-SSRS reports, the incidence of
suicidal ideation was low and similar between placebo (2%) and
cariprazine (3%) groups.
4. Discussion
Cariprazine 3–12 mg/day was effective and generally well
tolerated in the treatment of acute manic or mixed episodes
Table 2
Efﬁcacy parameters (MMRM, ITT population).
Efﬁcacy measure Placebo n¼152 Cariprazine n¼158 LSMD (95% CI) P value
Primary outcome
YMRS total score Baseline, mean (SD) 32.1 (5.6) 32.3 (5.8) – –
LS mean change from baseline to Week 3 (SE) 15.3 (0.9) 19.6 (0.9) 4.3(6.7, 1.9) 0.0004
Secondary outcome
CGI-S Baseline, mean (SD) 4.6 (0.6) 4.6 (0.6) – –
LS mean change from baseline to Week 3 (SE) 1.5 (0.1) 1.9 (0.1) 0.4(0.7, 0.1) 0.0027
Additional outcomes
CGI-I LS Mean Score at Week 3 (SE) 2.5 (0.1) 2.0 (0.1) 0.5(0.7, 0.2) 0.0004
PANSS total score Baseline, mean (SD) 60.4 (13.4) 61.0 (13.1) – –
LS mean change from baseline to Week 3 (SE) 13.2 (0.8) 16.5 (0.8) 3.3(5.5, 1.1) 0.0035
MADRS total score Baseline, mean (SD) 8.2 (4.1) 8.3 (4.0) – –
LS mean change from baseline to Week 3 (SE) 3.3 (0.4) 3.7 (0.4) 0.3(1.5, 0.8) 0.5626
YMRS responsea Patients with Z50% reduction from baseline at Week 3, n (%) 67 (44.1) 93 (58.9) – 0.0097
YMRS remissiona Patients with YMRS score r12 at Week 3, n (%) 53 (34.9) 82 (51.9) – 0.0025
a LOCF approach. CGI-I indicates Clinical Global Impressions-Improvement; CGI-S, CGI-Severity; CI, conﬁdence interval; LSMD, least squares mean difference; MADRS,
Montgomery–Åsberg Depression Rating Scale; PANSS, Positive and Negative Syndrome Scale; SD, standard deviation; SE, standard error; YMRS, Young Mania Rating Scale.
Fig. 1. Least squares mean change from baseline to week 3 in (A) Young Mania
Rating Scale (YMRS) total score and (B) Clinical Global Impressions-Severity (CGI-S)
score. Mixed-effects model with repeated measures (MMRM) analyses based on the
intent-to-treat population. nPo0.05 versus placebo; nnPo0.01 versus placebo;
nnnPo0.001 versus placebo.
G.S. Sachs et al. / Journal of Affective Disorders 174 (2015) 296–302 299
associated with bipolar I disorder. Cariprazine demonstrated sig-
niﬁcant improvement versus placebo on the primary and second-
ary efﬁcacy parameters, change from baseline to Week 3 in YMRS
total score and CGI-S score, respectively. Signiﬁcant differences on
both measures were evident at the ﬁrst postbaseline assess-
ment (Day 4) and were maintained throughout the duration of
the study, suggesting an early onset of effect with cariprazine
treatment.
The calculated effect size of cariprazine on the YMRS was 0.45
using MMRM and 0.40 using LOCF. In 2 previous bipolar mania
studies, cariprazine effect sizes (LOCF) were 0.57 (3–12 mg/day)
(Durgam et al., 2014), 0.58 (3–6 mg/day) (Calabrese et al., in press),
and 0.53 (6–12 mg/day) (Calabrese et al., in press). Relative to
effect sizes reported for other antimanic treatments in a recent
meta-analysis (Yildiz et al., 2011), the effect size of cariprazine in
this study was comparable with other atypical antipsychotics
(range, 0.26 [aripiprazole] to 0.66 [risperidone]).
Cariprazine treatment was also associated with high rates of
response (59%) and remission (52%) relative to placebo (response,
44%; remission, 35%) in this study. These response and remission
rates yielded number needed to treat (NNT) values of 7 and 6,
respectively. This was a similar ﬁnding to 2 previous cariprazine
studies in acute mania, which reported NNTs of 5 for response
(both studies) and 6 to 7 for remission (Calabrese et al., in press;
Durgam et al., 2014). The NNT for remission, the gold standard of
treatment in bipolar mania (Sachs and Rush, 2003), compared
favorably with other atypical antipsychotics, which as a group
showed an NNT of 8 based on a recent meta-analysis (Tamayo
et al., 2010).
The robust efﬁcacy with cariprazine in patients with bipolar
mania may be related to its novel pharmacological proﬁle. Car-
iprazine shows high afﬁnity and occupancy at D2 and D3 receptors
(Kiss et al., 2012, 2010). Blockade of the D2 receptor is thought
to underlie the basic antimanic effects of most antipsychotics
(Harrison-Read, 2009). Recent evidence suggests that the anti-
manic activities of both mood stabilizers (eg, lithium and valpro-
ate) and antipsychotics may also be at least partially mediated by
the GSK-3 signaling pathway (Beaulieu et al., 2009). Interestingly,
activity at D3 receptors has been shown to enhance D2 receptor-
mediated GSK-3 signaling (Beaulieu et al., 2007). Recent ﬁndings
demonstrate that cariprazine inhibits D2 receptor/ß-arrestin 2-
dependent interactions at a potency equivalent to haloperidol and
approximately 5-fold greater than that of aripiprazole (Gao et al.,
2014). Thus, the high afﬁnity and potent partial agonist activity of
cariprazine at D3 receptors may also contribute to the strong
antimanic efﬁcacy observed with cariprazine in the Phase II/III
clinical trials.
Cariprazine was generally well tolerated in this study, with
most TEAEs classiﬁed as mild or moderate in intensity. SAEs were
uncommon and there were no signiﬁcant differences between
treatment groups in rates of discontinuations due to TEAEs.
Cariprazine compared with placebo was associated with a greater
incidence of EPS-related TEAEs in this study and increased
incidence of parkinsonism and akathisia as assessed by the SAS
and BARS, respectively. EPS-related TEAEs (including akathisia and
restlessness) were generally mild to moderate in intensity and
typically did not result in discontinuation of treatment.
Antipsychotic treatment is also commonly associated with
weight gain, metabolic issues, increases in prolactin, sedation,
and QTc prolongation. In this study, mean changes in body weight
and metabolic parameters were generally small and similar
between cariprazine and placebo groups, suggesting that caripra-
zine may have a favorable metabolic proﬁle. As the treatment
period in this study was only 3 weeks, longer studies are needed
to better characterize the metabolic effects of cariprazine.
Table 3
Treatment-emergent adverse events during double-blind treatment phase (safety
population).
Preferred term Placebo n (%)
n¼154
Cariprazine n (%)
n¼158
Double-blind
Deaths 0 0
Patients with any TEAE 97 (63.0) 127 (80.4)
AE leading to discontinuation 11 (7.1) 15 (9.5)
Patients with SAE 3 (1.9) 5 (3.2)
Safety follow-up
Deaths 0 0
Patients with any TEAE 29 (18.8) 23 (14.6)
Patients with SAE 2 (1.3) 1 (0.6)
Frequent TEAEs (45% in either
treatment group)
Akathisia 7 (4.5) 35 (22.2)
Extrapyramidal disorder 3 (1.9) 24 (15.2)
Headache 16 (10.4) 18 (11.4)
Tremor 6 (3.9) 18 (11.4)
Dyspepsia 5 (3.2) 17 (10.8)
Nausea 10 (6.5) 16 (10.1)
Vomiting 6 (3.9) 16 (10.1)
Constipation 10 (6.5) 13 (8.2)
Dizziness 6 (3.9) 13 (8.2)
Diarrhea 2 (1.3) 11 (7.0)
Insomnia 8 (5.2) 9 (5.7)
Somnolence 2 (1.3) 9 (5.7)
Restlessness 1 (0.6) 9 (5.7)
Abdominal discomfort 6 (3.9) 8 (5.1)
Pyrexia 3 (1.9) 8 (5.1)
TEAE, treatment-emergent adverse event; SAE, serious adverse event.
Table 4
Changes from baseline to endpoint in clinical laboratory values and safety
parameters (safety population).
Placebo n¼154 Cariprazine n¼158
n
Mean change
(SD)
n
Mean change
(SD)
Liver function
Alanine aminotransferase, U/L 145 7.4 (25.6) 153 13.1 (37.6)
Aspartate aminotransferase,
U/L
145 1.1 (11.8) 153 3.4 (21.8)
Total bilirubin, mg/dL 145 0.1 (0.3) 153 0.1 (0.3)
Metabolic parameters
Total cholesterol, mg/dL 145 11.2 (28.6) 153 2.7 (30.1)
LDL cholesterol, mg/dL 143 8.3 (24.8) 148 1.3 (25.5)
HDL cholesterol, mg/dL 145 0.8 (10.0) 153 0.2 (9.4)
Triglycerides, mg/dL 145 8.9 (79.0) 153 14.5 (101.3)
Glucose, fasting, mg/dL 131 1.1 (17.4) 135 6.2 (15.9)
Other laboratory parameters
Prolactin, ng/mL 136 5.5 (17.8) 140 6.7 (17.3)
Creatine kinase, U/L 145 20.5 (234.5) 153 1.8 (163.5)
Vital signs
Systolic blood pressure,
mmHg 152 0.5 (10.6) 158 1.8 (10.1)
Diastolic blood pressure,
mmHg 152 0.6 (6.8) 158 1.4 (7.4)
Pulse, bpm 152 0.9 (11.6) 158 2.7 (12.3)
Body weight, kg 152 0.3 (2.0) 158 0.4 (2.0)
Waist circumference, cm 143 0.1 (4.1) 140 0.2 (2.8)
Extrapyramidal symptoms
AIMS total score 152 0.0 (0.3) 158 0.2 (0.8)
BARS total score 152 0.0 (0.8) 158 0.5 (1.5)
SAS total score 152 0.1 (0.8) 158 1.0 (3.0)
AIMS indicates Abnormal Involuntary Movement Scale; BARS, Barnes Akathisia
Rating Scale; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SAS,
Simpson-Angus Scale.
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Additionally, cariprazine was not associated with elevated prolac-
tin levels, cardiovascular AEs, including QTc prolongation and
tachycardia, or sedation (o3% of patients); the incidence of
somnolence was modestly higher for cariprazine (6%) than
placebo (1%).
The safety and tolerability of cariprazine may be related to its
mechanism of action and distinct receptor binding proﬁle. For
example, minimal interaction with 5-HT2C and H1 receptors may
reduce the potential for antipsychotic-induced weight gain
(Kroeze et al., 2003; Tecott et al., 1995) and lack of prolactin
elevation may suggest that the partial agonist activity of caripra-
zine at the D2 receptor may not impair normal function of the
tuberoinfundibular pathway (Stahl, 2003). Additionally, low afﬁ-
nity at adrenergic and cholinergic receptors and low potential for
inhibiting hERG channel activity may underpin the lack of cardi-
ovascular AEs (Leung et al., 2012), while minimal afﬁnity for
histaminergic receptors may explain the low incidence of sedation
(Richelson, 2010) observed with cariprazine treatment. Conver-
sely, because D2 blockade in the dopamine nigrostriatal pathway is
a mechanism that is common to antipsychotic medications, EPS
and akathisia are tolerability issues observed across the class
(Stahl, 2003).
Similar to other acute mania studies, this study had several
limitations. The inclusion/exclusion criteria may limit the ability to
generalize the ﬁndings to all patients in clinical practice. In
addition, while the 3-week study duration was sufﬁcient to assess
cariprazine in the treatment of acute bipolar mania, data from
longer studies are needed to evaluate the long-term efﬁcacy and
tolerability of cariprazine. Furthermore, this study utilized a
ﬂexible-dose study design. While this design allowed each indivi-
dual patient to receive an optimum dosage of cariprazine, no
conclusions could be drawn regarding the effects of different
cariprazine doses on efﬁcacy or tolerability outcomes. Finally, the
lack of an active comparator prevents deﬁnitive conclusions
regarding the comparative efﬁcacy relative to other bipolar mania
treatments.
In summary, cariprazine 3–12 mg/day was effective and gen-
erally well tolerated in this Phase III clinical trial in patients with
acute manic or mixed episodes associated with bipolar disorder.
The current results support earlier positive Phase II (Durgam et al.,
2014) and Phase III clinical trials (Calabrese et al., in press) that
demonstrated strong efﬁcacy and acceptable tolerability. Caripra-
zine with its distinct pharmacological proﬁle may provide a useful
new treatment option for bipolar mania.
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